- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04684342
Fungal Infection in Patients in Intensive Care Units
Predictors of Fungal Infection in Non-neutropenic Patients in Intensive Care Units
Predictors of fungal infection in non-neutropenic patients in intensive care units and the aim of the study is To evaluate the frequency of fungal infection in non-neutropenic patients in Intensive Care Units.
To evaluate the risk factors of fungal infection in these patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The incidence of candidemia in the overall population ranges from 1.7 to 10 episodes per 100,000 inhabitants and Candida is one of the ten leading causes of bloodstream infections in developed countries. An estimated 33-55% of all episodes of candidemia occur in intensive care units (ICU) and are associated with mortality rates ranging from 5% to 71%. Candida fungemia may have an endogenous or an exogenous origin, and in recent years a growing proportion of episodes of candidemia have been caused by Candida species other than albicans. The most important independent conditions predisposing to candidemia in ICU patients include prior abdominal surgery, intravascular catheters, acute renal failure, parenteral nutrition, broad-spectrum antibiotics, a prolonged ICU stay, the use of corticosteroids and mucosal colonization with Candida. In recent years, several studies have shown that ICU patients with mucosal Candida colonization, particularly if multifocal, are at a higher risk for invasive candidiasis, and that colonization selects a population amenable to antifungal prophylaxis or empirical therapy. Candidemia in ICUs is associated with a con- siderable increase in hospital costs and length of hospital stay.
Invasive fungal infection (IFI) is a grave infection associated with serious effects in patients with chronic diseases including liver cirrhosis. The diagnosis of IFI re- quires histopathological evidence of tissue invasion, or isolation in blood cultures, or isolation from a normally sterile body fluid or site, with samples collected intra-op- eratively or by percutaneous needle aspiration. Awareness of IFI has been increased in clinical practice with the increased survival of patients in immunocompromised states. Such infections are associated with a high morbidity and significant mortality, requiring early diagnosis and appropriate treatment, but also optimal prophylaxis in patients at high risk.
Globally, several studies had assessed fungal infections in non-neutropenic patients, however, to our knowledge, searching for fungal infections in these patients are un- derestimated in our locality.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult Patients with liver cirrhosis that will be clinically suspected to have in- fection.
Exclusion Criteria:
- Age < 18 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cirrhotic ICU Patients
about 150 patients with cirrhosis fulfill- ing the inclusion criteria that will be admitted to Tropical Medicine and Gas- troenterology Department, Al-Rajhi Liver Hospital, Assiut University Hospi- tals) will be evaluated for fungal infection.
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
frequency of fungal infection in cirrhotic patients
Time Frame: 4 months
|
frequency of fungal infection in cirrhotic patients
|
4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Mohamed Zakaria, Professor, Assiut University
Publications and helpful links
General Publications
- Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013 Apr;57(4):1651-3. doi: 10.1002/hep.26359. No abstract available.
- Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet. 2006 Jan 7;367(9504):52-6. doi: 10.1016/S0140-6736(06)67924-5. Erratum In: Lancet. 2006 Feb 25;367(9511):650.
- Bucsics T, Schwabl P, Mandorfer M, Peck-Radosavljevic M. Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). J Hepatol. 2016 Jun;64(6):1452-4. doi: 10.1016/j.jhep.2016.01.039. Epub 2016 Feb 23. No abstract available.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Fungal infection in ICU
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fungal Infection
-
Radboud University Medical CenterCompletedInvasive Fungal InfectionNetherlands
-
People's Hospital of Zhengzhou UniversityCompletedAn Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDMInvasive Fungal InfectionChina
-
Grupo de Estudio de Infecciones en TransplantadosMerck Sharp & Dohme LLCUnknownLiver Transplantation | Fungal InfectionSpain
-
Bayside HealthMerck Sharp & Dohme LLCUnknownFungal InfectionAustralia
-
University of PittsburghSchering-PloughTerminatedFungal InfectionUnited States
-
Daping Hospital and the Research Institute of Surgery...RecruitingInvasive Fungal Infection | Neonatal Infection | Plasma AdministrationChina
-
Merck Sharp & Dohme LLCRecruitingInvasive Fungal InfectionIsrael, United States, Belgium, Greece, Peru, Poland, Mexico, Russian Federation
-
Merck Sharp & Dohme LLCCompleted
-
University of PittsburghAstellas Pharma US, Inc.Completed
-
Ruijin HospitalMerck Sharp & Dohme LLCUnknown
Clinical Trials on Routine Laboratory investigations
-
Assiut UniversityAliae AR Mohamed Hussein [ahusseinRecruiting
-
Medical University of ViennaRecruitingViral Myocarditis | POTS | Post Viral FatigueAustria
-
Sohag UniversityNot yet recruitingImmune Thrombocytopenic Purpura
-
Sohag UniversityNot yet recruitingAcute Necrotizing EncephalopathyEgypt
-
Assiut UniversityCompleted
-
Sohag UniversityNot yet recruiting
-
Hillel Yaffe Medical CenterUnknown
-
Saint-Joseph UniversityUnknownMultiple Sclerosis | Urinary Bladder, Neurogenic | UrodynamicsLebanon
-
Assiut UniversityRecruitingWhether Osteocrin Levels Are Associated With Glycemic Control, Vascular Disorders in Diabetic PatientsEgypt
-
Institut de cancérologie Strasbourg EuropeCompletedVaginal Cancer | Prostate Carcinoma | Radiotherapy | Rectum Carcinoma | Cervix Carcinoma | Anal Canal Carcinoma | Endometrium CarcinomaFrance